middle.news
Nexsen’s FlashDx partnership opens a second route into GBS diagnostics
9:40am on Friday 25th of September, 2026 AEST
•
Healthcare and Biotechnology
Read Story
Nexsen’s FlashDx partnership opens a second route into GBS diagnostics
9:40am on Friday 25th of September, 2026 AEST
Key Points
50:50 non-binding JV with FlashDx Shenzhen
Existing CE-marked molecular GBS test provides the technical base
Nexsen to fund and lead planned FDA 510(k) and CE-IVDR pathways
Separate hospital and intrapartum product alongside StrepSure
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexsen (ASX:NXN)
OPEN ARTICLE